Technology | Patient Positioning Radiation Therapy | October 19, 2015

Orfit Announces CE, FDA Clearance for Proton Therapy Immobilization System

HP Pro Solution designed for high-precision immobilization, patient comfort in brain, head and neck treatments

Orfit Industries, HP Pro Solution, proton therapy immobilization system, ASTRO 2015, CE Mark, FDA clearance

Image courtesy of Orfit Industries

October 19, 2015 — Orfit Industries introduced and demonstrated its HP Pro Solution, an innovative, comprehensive and versatile immobilization system for proton therapy, at the American Society for Radiation Oncology (ASTRO) 57th annual meeting. The technology, designed for brain, head and neck treatments, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

When used with Orfit’s ultra-thin and stable Nanor immobilization masks, based on nanotechnology, HP Pro offers a unique combination of high-precision immobilization and patient comfort.

The British Royal Infirmary in Bristol, United Kingdom, has recently introduced a new gamma knife treatment using the Orfit radiotherapy mask. The treatment has been welcomed by specialists as a non-invasive, potential life-saver, helping to kill off unwanted growths of brain tumors with one millimeter precision, without harming healthy brain tissue.

The HP Pro hardware is designed for use in both proton and photon therapy. The products are homogenous, low density, lightweight and available in a range of configurations including overlays, extensions and a combination overlay/extension in one product. A full range of accessories, including patient-customized head rests, is available.

For more information: www.orfit.com

Related Content

Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...